Rokote Laboratories Finland Oy
2 clinical trials · Sponsor
◉ Watch Rokote Laboratories Finland Oy
| Record | Firm | Date |
|---|---|---|
| Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19 (NCT07416539) | Rokote Laboratories Finland Oy | 2026-02-10 |
| The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus (NCT06851611) | Rokote Laboratories Finland Oy | 2025-01-21 |
Track Rokote Laboratories Finland Oy automatically
Every clearance here is in the API, with alerts when new ones post.